We Provide Telemedicine to our patients. Schedule your Telemedicine appointment now.
Skip to main content

Interim Results From the Partnership for Advancement in Neuromodulation Pain Registry

Interim Results From the Partnership for Advancement in Neuromodulation Pain Registry



The objective of this study was to present results from a multicenter registry designed to obtain longitudinal clinical outcome data for patients implanted with a neuromodulation system for the management of chronic pain of the trunk and/or limbs.

Materials and Methods

Interim data from 579 patients across 40 study sites were analyzed from a prospective, observational, noninterventional registry. Institutional review board approval was obtained prior to enrollment. The following were recorded at baseline and at 3, 6, and 12 months postimplant: patient‐reported pain relief, categorical ratings of pain relief, Pain Disability Index (PDI) scores, quality of life, medication usage, and patient satisfaction. Pain relief among (tobacco) smokers was also assessed. Descriptive statistics were compiled for all patient outcome measurements, and data are reported as mean (±standard deviation). All statistical analysis was conducted using one‐sided t‐tests with a significance level of α = 0.05. Device‐related adverse events were captured and are reported.


Patient‐reported pain relief was 58.0% (±26.2%) at 3 months, 58.1% (±28.7%) at 6 months, and 57.0% (±29.4%) at 12 months. Mean PDI scores were reduced from 47.7 points at baseline to 33.3, 32.4, and 31.9 points, respectively (p ≤ 0.001). The majority of patients categorized their pain relief as “excellent” or “good” and reported their overall quality of life as “greatly improved” or “improved” at all time points. In addition, greater than 79% of patients were “satisfied” or “very satisfied” with the therapy at all time points assessed, and 47.1% of patients “stopped” or “decreased” use of narcotics/opioids. Pain relief was significantly attenuated by smoking (p = 0.042). The most common adverse event was persistent pain and/or numbness at implantable pulse generator/lead site, which accounted for 18.6% of all events in 3.2% of all patients.


These results provide evidence to further support the safety, efficacy, and sustainability of neuromodulation in clinical practice.

Read the full journal article here

You Might Also Enjoy...

Radiofrequency Ablation : A back pain treatment that works

Back pain is one of the most common reasons a patient comes to a pain management physician's clinic due to spine facet osteoarthritis. Radiofrequency ablation of the spinal facet joints represents the standard of care for long term pain relief.

An Update from the Expert Pain Team about Care During COVID

The headlines tell us that there is light at the end of the COVID-19 tunnel, with vaccine distribution beginning in the next few weeks. But it will be several months before the majority of the population can be vaccinated, so it is critical that....

Conditions that Cause Leg Pain

When people experience pain in their legs, it can fall into two major categories: acute or chronic. Acute pain comes on suddenly and is often caused by injury or damage to the bones, tendons or ligaments in the legs.

Spinal Cord Stimulation for Neuropathic Pain

The body’s nervous system can be thought of as a “hub and spoke” model, where the hub (the brain) serves as the central control room that sends and receives messages from the spokes, the nerves in the spinal cord, skin, muscles and other parts of the body.

Interventional Treatment Options for Back Pain

The human spine consists of 24 separate vertebrae interspaced with cartilage, plus the two bones of the sacrum and coccyx. Supporting these bones are 23 discs, more than 30 muscles and tendons that provide spinal balance, stability and mobility...